No significant difference in DVT incidence between aspirin vs rivaroxaban in total knee arthroplasty .
Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban
Rev Bras Ortop. 2017 Dec 6;53(1):22-2732 patients scheduled for total knee arthroplasty were randomized to thromboprophylaxis with either rivaroxaban 10mg daily or aspirin 300mg daily for 14 days after surgery. Patients were assessed for deep vein thrombosis rate, local complication rate, systemic complication rate, reoperation rate, mortality rate, postoperative blood loss, and hemoglobin and hematocrit drop. Of primary consideration, analyses demonstrated no significant difference in the rate of deep vein thrombosis between groups, as well as no significant difference in 48-hr postoperative blood loss between groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
